Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the quarter ended September 30, 2015. The report was signed on October 30, 2015. The entity is an Australian biotechnology company admitted to the ASX on the basis of commitments, focusing on research and development activities.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Revenue (Receipts from customers) | 0 |
| Net Operating Cash Flows | (4,572) |
| Net Investing Cash Flows | 0 |
| Net Financing Cash Flows | 0 |
| Cash at Beginning of Quarter | 35,062 |
| Cash at End of Quarter | 32,988 |
| Research and Development Costs | (3,161) |
| Staff Costs | (723) |
| Debt/Borrowings | 0 |
The filing does not provide a clear value for net profit or loss, as it focuses on cash flows. The company received $56,000 in grants/donations and $51,000 in interest income during the period.
Material Changes
The filing presents data for the current quarter and year-to-date (3 months) as identical figures, indicating no material change in the cumulative position versus the prior comparable period within this specific reporting window. The cash balance decreased by approximately $2.1 million from the previous quarter's end ($35,062) to the current quarter's end ($32,988), primarily due to operating outflows.
Outlook, Risks, and Commentary
The filing contains no specific management commentary, forward-looking guidance, or explicit risk factors beyond the standard disclosure requirements for entities admitted on the basis of commitments. The company reported no acquisitions, disposals, or new financing facilities during the quarter. Related party payments totaled $301,000, described as salaries, directors' fees, and consulting fees at normal commercial rates.
Investor Verification Checklist
- Verify the company's cash runway given the negative operating cash flow of $4.572 million and zero revenue.
- Confirm the status of the $56,000 in grants received and any conditions attached to future funding.
- Review the specific R&D milestones achieved for the $3.161 million spent during the quarter.
- Check for any subsequent capital raising activities not reflected in this October 30 filing.